Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (10247)	12/17/2008 6:50:09 AM
From: Icebrg	of 10280

Piper Jaffray Initiates Coverage on Sepracor (SEPR) with a Neutral December 16, 2008 9:09 AM EST Piper Jaffray & Co. initiates coverage on Sepracor, Inc. (Nasdaq: SEPR) with a Neutral. Price target $11. Piper analyst says, "We are expecting a nearly flat year in 2009 for EPS amid heavy spending on R&D to combat the expected erosion of 80% of its revenue base due to launches of generic Xopenex UDV for asthma/COPD and Lunesta for insomnia (2012 and 2014, respectively). New products and pipeline products have only marginal differentiation, in our view, with near-term spending unlikely to bear fruit over the long-term. We believe investors would be well-served to look elsewhere given the questionable decisions by management to address long-term generic risks."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next